Reid Hoffman leaves Microsoft board to focus on AI startup
Reid Hoffman is leaving Microsoft's board after nearly a decade to focus on Manus, his AI drug discovery startup. He joined Microsoft in 2016 post the LinkedIn acquisition. Hoffman cited Manus' progress as the catalyst for his return to founder mode.
*this image is generated using AI for illustrative purposes only.
Reid Hoffman, co-founder of LinkedIn, is stepping down from Microsoft's board of directors to dedicate his full attention to Manus, his AI-powered drug discovery startup. Hoffman joined the board in 2016 following Microsoft's $26.2 billion acquisition of LinkedIn. His departure marks the end of a nearly decade-long tenure during which he witnessed key strategic moves, including a $1 billion investment in OpenAI in 2019 and the $650 million acqui-hire of Inflection AI.
Strategic Tenure
During his time on the board, Hoffman was present for several major initiatives. These included the landmark OpenAI investment and the acquisition of Inflection AI, which brought co-founder Mustafa Suleyman to Microsoft. Hoffman resigned from OpenAI's board in 2023 to avoid potential conflicts of interest with his investments through Greylock Partners and his personal holdings in startups utilizing OpenAI's technology.
Focus on Manus
Hoffman decided to leave Microsoft due to the rapid momentum at Manus. "We're seeing such progress with Manus. I need to get back to founder mode," Hoffman stated on his "Possible" podcast with Microsoft CEO Satya Nadella. Manus is an AI-native biopharmaceutical and cancer drug discovery company backed by Hoffman and General Catalyst. Hoffman serves as co-founder and chairman, while Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning physician, is the CEO.
Key Details
| Entity | Role/Value |
|---|---|
| Microsoft | Board tenure since 2016 |
| Acquired for $26.2 billion | |
| OpenAI | $1 billion investment in 2019 |
| Inflection AI | $650 million acqui-hire |
Hoffman believes Manus is advancing "Move 37" AI, a form of machine intelligence designed to surpass human creativity in chemistry to combat cancer.
How will Hoffman's departure influence Microsoft's future strategic direction regarding AI investments?
What are the potential market implications for Manus as Hoffman shifts his full focus to the startup?
Could this move signal a broader trend of tech leaders leaving corporate boards to pursue AI-driven ventures?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
